- Home
- SLN vs HUYA Comparison
SLN vs HUYA Comparison
Compare SLN & HUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- HUYA
- Stock Information
- Founded
- SLN 1994
- HUYA 2014
- Country
- SLN United Kingdom
- HUYA China
- Employees
- SLN N/A
- HUYA N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- HUYA Computer Software: Programming Data Processing
- Sector
- SLN Health Care
- HUYA Technology
- Exchange
- SLN Nasdaq
- HUYA Nasdaq
- Market Cap
- SLN 919.6M
- HUYA 929.0M
- IPO Year
- SLN N/A
- HUYA 2018
- Fundamental
- Price
- SLN $18.50
- HUYA $3.45
- Analyst Decision
- SLN Strong Buy
- HUYA Strong Buy
- Analyst Count
- SLN 4
- HUYA 4
- Target Price
- SLN $61.50
- HUYA $6.38
- AVG Volume (30 Days)
- SLN 179.3K
- HUYA 2.4M
- Earning Date
- SLN 11-12-2024
- HUYA 11-12-2024
- Dividend Yield
- SLN N/A
- HUYA N/A
- EPS Growth
- SLN N/A
- HUYA N/A
- EPS
- SLN N/A
- HUYA N/A
- Revenue
- SLN $22,623,125.00
- HUYA $858,652,794.00
- Revenue This Year
- SLN N/A
- HUYA N/A
- Revenue Next Year
- SLN $104.98
- HUYA $9.57
- P/E Ratio
- SLN N/A
- HUYA N/A
- Revenue Growth
- SLN N/A
- HUYA N/A
- 52 Week Low
- SLN $6.51
- HUYA $2.82
- 52 Week High
- SLN $27.72
- HUYA $6.84
- Technical
- Relative Strength Index (RSI)
- SLN 48.92
- HUYA 32.50
- Support Level
- SLN $18.20
- HUYA $5.24
- Resistance Level
- SLN $19.36
- HUYA $6.43
- Average True Range (ATR)
- SLN 0.88
- HUYA 0.34
- MACD
- SLN -0.04
- HUYA -0.23
- Stochastic Oscillator
- SLN 35.50
- HUYA 0.50
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Established in 2011, Huya is the largest online game livestreaming company in China. Headquartered in Guangzhou, Huya mainly provides livestreamed videos on esports games such as League of Legends and Honor of Kings and collects virtual tips from viewers. Its products include the Huya Live platform in China and Nimo TV in Southeast Asia and South America. As of 2023, Huya was a subsidiary of Tencent, which owned 63% of its equity stake and held 94% of the voting power.